Replies to post #105423 on Biotech Values

[genisi]

SNY’s lixisenatide achieved its primary endpoint of noninferiority to exenatide in Phase-3 trial:

http://www.prnewswire.com/news-releases/positive-top-line-phase-iii-data-in-type-2-diabetes-achieved-for-lixisenatide-once-daily-vs-exenatide-twice-daily-115083734.html